What's in Purdue Pharma LP's pipeline?

Purdue Pharma LP has 18 drugs in our index: 6 marketed, 0 filed, 6 in Phase 3, 5 in Phase 2, 1 in Phase 1.

Which companies overlap with Purdue Pharma LP's portfolio?

Top competitors by shared drug class: Labopharm Inc., Pfizer, Grünenthal GmbH, Janssen Korea, Ltd., Korea, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/purdue-pharma-lp.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Purdue Pharma LP — Portfolio Competitive Intelligence Brief

Purdue Pharma LP pipeline: 6 marketed, 0 filed, 6 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 6 Phase 3 5 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Chirocain	LEVOBUPIVACAINE	marketed	levobupivacaine	Cytochrome P450 2D6	Pain	1999-01-01
Subutex	BUPRENORPHINE	marketed	Partial Opioid Agonist	mu-opioid receptor, kappa-opioid receptor	Neuroscience	1981-01-01
Buprenorphine transdermal patch	Buprenorphine transdermal patch	marketed
Adhansia XR	Adhansia XR	marketed	Sympathomimetic amine combined with alpha-2A adrenergic agonist	Dopamine transporter, norepinephrine transporter, alpha-2A adrenergic receptor	Neurology / Psychiatry
Oxycodone HCl controlled-release	Oxycodone HCl controlled-release	marketed	Opioid analgesic	Mu (μ) opioid receptor	Pain Management
HYD	HYD	marketed	Opioid analgesic	Mu opioid receptor (μ-OR)	Pain Management
Placebo oxycodone/acetaminophen tablets	Placebo oxycodone/acetaminophen tablets	phase 3			Pain Management
Buprenorphine transdermal delivery system	Buprenorphine transdermal delivery system	phase 3	Partial mu-opioid receptor agonist	Mu-opioid receptor (μ-OR)	Pain Management; Opioid Use Disorder
OXY/APAP	OXY/APAP	phase 3	Opioid analgesic combination	Mu opioid receptor (oxycodone); COX inhibition and monoamine modulation (acetaminophen)	Pain Management
Oxycodone/Naloxone controlled-release	Oxycodone/Naloxone controlled-release	phase 3	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonist)	Pain Management
Oxycodone HCl controlled-release tablets	Oxycodone HCl controlled-release tablets	phase 3	Opioid analgesic	Mu (μ) opioid receptor	Pain Management
Placebo to match BTDS	Placebo to match BTDS	phase 3

Therapeutic area mix

Pain Management · 6
Infectious Disease · 1
Neurology / Psychiatry · 1
Neuroscience · 1
Pain · 1
Pain Management; Opioid Use Disorder · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-07-31 — Subutex · 8236755 · Formulation · US
2027-01-10 — Subutex · 8236292 · Formulation · US
2031-06-06 — Subutex · 9498432 · Formulation · US
2031-06-06 — Subutex · 9272044 · Method of Use · US
2031-06-06 — Subutex · 10198218 · Method of Use · US
2031-06-06 — Subutex · 10592168 · Method of Use · US
2031-06-06 — Subutex · 9782402 · Formulation · US
2031-06-06 — Subutex · 9827241 · Formulation · US
2031-06-25 — Subutex · 10558394 · Formulation · US
2031-09-05 — Subutex · 8975270 · Formulation · US
2032-01-06 — Subutex · 8921387 · Formulation · US
2032-07-26 — Subutex · 11135215 · Formulation · US
2032-07-26 — Subutex · 12318379 · Formulation · US
2032-07-26 — Subutex · 12161640 · Formulation · US
2032-07-26 — Subutex · 11110084 · Formulation · US
2032-07-26 — Subutex · 10912772 · Method of Use · US
2032-07-26 — Subutex · 9937164 · Formulation · US
2035-11-06 — Subutex · 11839611 · Method of Use · US
2035-11-06 — Subutex · 11000520 · Method of Use · US
2038-06-22 — Subutex · 10646484 · Method of Use · US

Competitive overlap (companies sharing drug classes)

Labopharm Inc. · 2 shared drug classes
Pfizer · 2 shared drug classes
Grünenthal GmbH · 2 shared drug classes
Janssen Korea, Ltd., Korea · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Mundipharma (China) Pharmaceutical Co. Ltd · 2 shared drug classes
BioDelivery Sciences International · 2 shared drug classes
Tel-Aviv Sourasky Medical Center · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Purdue Pharma LP:

Cite this brief

Drug Landscape (2026). Purdue Pharma LP — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/purdue-pharma-lp. Accessed 2026-05-13.